Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer

Hormone Sensitive

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-011-1351-3 ◽

2011 ◽

Vol 126 (2) ◽

pp. 295-310 ◽

Cited By ~ 60

Author(s):

Susan F. Dent ◽

Rania Gaspo ◽

Michelle Kissner ◽

Kathleen I. Pritchard

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Management Strategies ◽

Inhibitor Therapy ◽

Hormone Sensitive

Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial

Contemporary Clinical Trials ◽

10.1016/j.cct.2011.04.012 ◽

2011 ◽

Vol 32 (5) ◽

pp. 704-709 ◽

Cited By ~ 5

Author(s):

Sharon Kilbreath ◽

Kathryn M. Refshauge ◽

Jane Beith ◽

Leigh Ward ◽

Kate Sawkins ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Controlled Trial ◽

Inhibitor Therapy ◽

Randomized Controlled ◽

Prevention Of Osteoporosis

Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis

Archives of Medical Research ◽

10.1016/j.arcmed.2014.10.007 ◽

2014 ◽

Vol 45 (7) ◽

pp. 570-579 ◽

Cited By ~ 3

Author(s):

Guoqiang Su ◽

Yi Xiang ◽

Guodong He ◽

Chenchun Jiang ◽

Chuang Li ◽

...

Keyword(s):

Breast Cancer ◽

Bone Loss ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Meta Analysis ◽

Inhibitor Therapy ◽

Aromatase Inhibitor Therapy

0134 CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer

The Breast ◽

10.1016/s0960-9776(09)70166-3 ◽

2009 ◽

Vol 18 ◽

pp. S52 ◽

Cited By ~ 1

Author(s):

P. Neven ◽

D. Serin ◽

R. Separovic ◽

C. Ozaslan ◽

M. Tanner

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Educational Material ◽

Study Evaluation ◽

Persistence Rates ◽

Hormone Sensitive ◽

The Impact

Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy

JAMA Network Open ◽

10.1001/jamanetworkopen.2019.11080 ◽

2019 ◽

Vol 2 (9) ◽

pp. e1911080 ◽

Cited By ~ 3

Author(s):

Rebecca Pedersini ◽

Vito Amoroso ◽

Filippo Maffezzoni ◽

Fabio Gallo ◽

Antonella Turla ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Body Mass ◽

Early Breast Cancer ◽

Vertebral Fractures ◽

Fat Body ◽

Inhibitor Therapy ◽

Review for "The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy"

10.1002/jbm4.10440/v2/review1 ◽

2020 ◽

Author(s):

David Scott

Keyword(s):

Breast Cancer ◽

Vertebral Fracture ◽

Aromatase Inhibitor ◽

Lean Body Mass ◽

Body Mass ◽

Early Breast Cancer ◽

Fat Body ◽

Fracture Prevalence ◽

Review for "The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy"

10.1002/jbm4.10440/v1/review1 ◽

2020 ◽

Author(s):

David Scott

Keyword(s):

Breast Cancer ◽

Vertebral Fracture ◽

Aromatase Inhibitor ◽

Lean Body Mass ◽

Body Mass ◽

Early Breast Cancer ◽

Fat Body ◽

Fracture Prevalence ◽

The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy

JBMR Plus ◽

10.1002/jbm4.10440 ◽

2020 ◽

Author(s):

Sara Monteverdi ◽

Rebecca Pedersini ◽

Fabio Gallo ◽

Filippo Maffezzoni ◽

Alberto Dalla Volta ◽

...

Keyword(s):

Breast Cancer ◽

Vertebral Fracture ◽

Aromatase Inhibitor ◽

Lean Body Mass ◽

Body Mass ◽

Early Breast Cancer ◽

Fat Body ◽

Fracture Prevalence ◽

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70770-x ◽

2007 ◽

Vol 5 (4) ◽

pp. 186-187 ◽

Cited By ~ 21

Author(s):

N. Schenk ◽

A. Lombart ◽

A. Frassoladti ◽

P. Neven ◽

G. Jerusalem ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer

The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.

10.1158/0008-5472.sabcs-44 ◽

2009 ◽

Cited By ~ 21

Author(s):

H Eidtmann ◽

NJ Bundred ◽

R DeBoer ◽

A Llombart ◽

N Davidson ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer